SSA
MCRB icon

Schonfeld Strategic Advisors’s Seres Therapeutics MCRB Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,000
Closed -$2.38M – 2338
2021
Q2 		$2.38M Buy
+5,000
New +$2.11M 0.03% 658

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's MCRB Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Seres Therapeutics (MCRB) in Q1 2026, closing a stake of 29,097 shares — an estimated $433K sold.

Schonfeld Strategic Advisors first reported a position in MCRB in Q3 2020 and held it in 10 quarters. The position peaked at $2.54M in Q2 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Seres Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 29,097 Seres Therapeutics shares in Q1 2026, an estimated $433K.
  • Schonfeld Strategic Advisors first reported a position in Seres Therapeutics in Q3 2020 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Seres Therapeutics position peaked at $2.54M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.